EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
Read Article
Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://t.co/AmG6hkWABW https://t.co/MYhkfxAh0r
Dr. John Cush @RheumNow( View Tweet )
True or False: In a meta-analysis, RA was associated with a significantly increased risk of osteoporotic fractures in female patients but not in male patients. See if you got it right in the latest RheumIQ quiz at https://t.co/HCxOwRl2Tq. https://t.co/O9WRKQKmu4
Dr. John Cush @RheumNow( View Tweet )
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA
After the first tumor necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab. https://t.co/Cml3Z7ZyQP
Dr. John Cush @RheumNow( View Tweet )
EULAR Recommendations for Physical Activity in Arthritis
EULAR has published a 2025 update for physical activity recommendations for patients with osteoarthritis (OA) and rheumatoid arthritis (RA).
https://t.co/RFECflCUgf https://t.co/Da7D6KpN6q
Dr. John Cush @RheumNow( View Tweet )
Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://t.co/RS3BvufE7F https://t.co/cxKk2xZmoS
Dr. John Cush @RheumNow( View Tweet )
Study of 216 RA pts - Serum IL-8 independently assoc w/ RA Dz activity. CRP & IL-6 significantly associated w/ higher IL-8 levels, but RF & CCP did not. IL-8 also correlated w/ CV risk (SCORE2) & carotid intima media thickness https://t.co/aqUoAeXFFP https://t.co/ZW7OAx8YGK
Links:
Dr. John Cush @RheumNow( View Tweet )
Dental study from India assessed periodontal Dz (PD) in 170 RA vs 170 non-RA pts. RA had more PD, ^ESR, more mild PD (39% v 29%). DAS-28 correlated w/ PD severity. Pts w/ periodontitis had 3X ods of RA (OR = 2.9) /https://t.co/bvOnFzbRcd https://t.co/cSxfiIR4iS
Links:
Dr. John Cush @RheumNow( View Tweet )
Danish registry study of truncal (2,260) vs superselective (3,810) vagotomy (1977-95) vs general popul. (10:1). Truncal incr. RA risk (aHR 2.62), but selective did not (aHR 1.05. Neither had effect on OA risk https://t.co/dqejtN9TwY https://t.co/R0OJZTxd5T
Dr. John Cush @RheumNow( View Tweet )
Smoking is most established environmental risk factor for RA- Dz risk, severity, & RA-ILD. Role of other airborne pollutants is mixed: particulate matter & nitrogen dioxide show inconsistent associations w/ RA https://t.co/Fkemc5hAUB
Dr. John Cush @RheumNow( View Tweet )
Switch or Cycle - Upadacitinib vs Adalimumab in Refractory RA
After the first tumour necrosis factor inhibitor (TNFi) failure, patients with active rheumatoid arthritis (RA) responded by switching to upadacitinib, compared to cycling to a second TNFi, adalimumab.
Arthralgia w/ HIGH ACPA level >3x ULN) has a 30–50% probability of being diagnosed with RA within 3–5 years https://t.co/iJTyMQM480
Dr. John Cush @RheumNow( View Tweet )
https://t.co/4UQlqwujiR 2026 brought together leading rheumatology experts for two days of practical, clinically focused education.
Now you can watch the full program On Demand.
Highlights include:
• RA mortality trends and the mucosal hypothesis
• IL-23 vs IL-17 inhibitor https://t.co/YMfxa7PDXF
Links:
Dr. John Cush @RheumNow( View Tweet )
Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than placebo & equal to MTX regarding annual xray progression scores. Evidence in favor BUT failed to study monoRx vs Combo Rx https://t.co/cMSZ4QHi5G https://t.co/o9ikhJu3UM
Dr. John Cush @RheumNow( View Tweet )
TriNetX study of 7,929 RA pts Rx w/ bDMARDs (n 2668) w/in 6 mos of elective hand surgery - perioperative bDMARD continuation (34%) was not associated with significant increases in risks of wound healing failures (1.4% vs 1.4%) or SSI (2% vs 1.5%) https://t.co/NY6l2jRswb https://t.co/IxoYtLNGvf
Links:
Dr. John Cush @RheumNow( View Tweet )
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Elena Myasoedova examines mortality trends in RA, exploring whether we are seeing continued decline, delayed impact, or a concerning https://t.co/yUob3Tv0tR
Links:
Dr. John Cush @RheumNow( View Tweet )
Follow the Money (4.23.2026)
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Read Article
Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM https://t.co/QP8YdX7CcH
Dr. John Cush @RheumNow( View Tweet )
Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than placebo & equal to MTX regarding annual xray progression scores. Evidence in favor BUT failed to study monoRx vs Combo Rx https://t.co/eHdRPAcnkd https://t.co/1odwJjyL6A
Dr. John Cush @RheumNow( View Tweet )
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and implications.
🎧 Listen here: https://t.co/ehPLdB4byb
#Rheumatology #Autoimmunity #RNL2026 https://t.co/nLEPM3REi4
Dr. John Cush @RheumNow( View Tweet )
Leeds study of 63 pts w/ palindromic rheumatism (PR) progressed to Persistent IA (PIA) @ median 13.4 mos, hands predominating across flares. PIA developed in joints involved in PR flares in 71% of pts. @RA Dx, PR onset pts had signif higher swollen joints(4.1 vs 3.2) https://t.co/g2vjfVjDlK
Dr. John Cush @RheumNow( View Tweet )
Retrospective observational study of IPAF (ILD w/ autoimmune) pts - from Mt Sinai ILD registry 791 - 14 Rx w/ rituximab vs 19 not. Betw group outcomes same: PFTs, O2 use, Infx, Resp admissions, mortality. RTX group recv more immunosuppressives. https://t.co/sle4a0JOFL https://t.co/rS69epQiif
Dr. John Cush @RheumNow( View Tweet )
Potential new mechanism of MTX Effx - MTX polyglutamates accumulates in monocytes by D5, modulates transcriptional signature “non-classical monocyte”-assoc genes by Wk4, & predicts MTX responses https://t.co/0HtvWOczba https://t.co/oIs4V34hw3
Dr. John Cush @RheumNow( View Tweet )
Malignancies Not Increased with Biologic Therapies
The risk of malignancy in RA patients receiving biologic agents was evaluated by metanalysis of RCTs and found no significant increased risk of malignancy compared with other DMARDs or with placebo.
https://t.co/ZEO4jP5RwA https://t.co/C1YeTSh7ZN
Dr. John Cush @RheumNow( View Tweet )
Rheumatoid Arthritis Faculty Panel Q&A
This expert panel from https://t.co/4UQlqwujiR 2026 brings together leading faculty to address real-world challenges in RA care, offering practical insights you can apply immediately in practice.
🎧 Listen here: https://t.co/LOiUuia852 https://t.co/REvpPJv0O8
Dr. John Cush @RheumNow( View Tweet )
Therapeutic Updates
Expert insights on the 2024 ACR Guideline recommendations for lupus nephritis
Sponsored by Aurinia
Two experts in lupus care offer a balanced perspective on applying the updated ACR Guideline recommendations and the clinical nuances of managing lupus nephritis.
Read Post
Recent Blogs
Podcasts
ACR 2025 RA Topic Podcasts Compilation 6
ACR 2025 Daily Podcasts Day4b-
ACR 2025 RA Topic Podcasts Compilation 5
